Domestic first imitation! Fangsheng Pharmaceuticals " E-folding wheat cloth tablets" was approved for listing.

E-folding mebu is a kind of blood lipid-lowering drug, is the first cholesterol absorption inhibitor, its main target is cholesterol transport protein NPC1L1.
This protein is a key protein in the cross-membrane transport of small intestine cholesterol, and by blocking its absorption of cholesterol, it reduces the transport of cholesterol from the intestines to the liver, reduces the amount of cholesterol stored in the liver, and accelerates the removal of cholesterol in the blood.
the drug was first developed by Shilling-Ya and later acquired by Mercadon.
approved by the U.S. FDA in 2002 for the treatment of primary hypercholesterolemia called Zetia / Ezetrol.
,000 million U.S. patents went public, with global sales growing rapidly, toping $2 billion in 2007 and stabilizing at $2.5 billion in the first five years of 2016 when its patents expired.
sales declined as patents expired and were hit by generics, with global sales of $590 million in 2019.
, the original drug was listed in 2006 and has been included in the National Health Insurance Category B directory.
According to the Insight database, in addition to the original drug research drug and the approved Hunan Fangsheng, four other enterprises are currently in the listing application stage, including Suzhou Huajian Rida, Chongqing Sanhua, Beijing Fuyuan three category 4 imitations and Sanders Pharmaceuticals 5.2 imports.
companies in the BE trial phase, including Jiangsu Haussen, Beijing Four Rings Pharmaceuticals, etc.
29 other companies have been approved for clinical start-up.
from: Insight Database ()